ABOUT US | South Rampart Pharma

ABOUT US

We are dedicated to advancing the treatment of pain

South Rampart Pharma,Inc. is a team of experienced clinicians, researchers, innovators and lead business management experts who recognized the immense burden placed on patients and the healthcare system from the limitations of available pain medicines—which is why we’ve set out to change the status quo.

Our small-molecule solutions have the potential to overcome many risks associated with current pain medicines, offering patients and clinicians a safer option for pain medicines. And because our molecule is not a biologic therapy, the end product should be low-cost and accessible to many patients.

Our Story

2016

South Rampart Pharma,Inc. was founded in 2016 to develop safer, non-opioid therapies for acute and chronic pain, addressing the significant unmet needs of patients and clinicians around the world.

September 15, 2020

The first manuscript describing novel analgesic compounds’ synthesis, lack of hepatoxicity, analgesic characterization, and antipyretic properties was published by our two co-founders.

September 25, 2020

Shortly after the manuscript was published, the NIH awarded South Rampart Pharma with a $1.9 million Fast-Track Small Business Technology Transfer (STTR) grant to further develop these promising compounds.

January 2022

The SRP-001 Phase 1 clinical trial began, enrolling 60 patients in a randomized, double-blind, placebo-controlled study with endpoints assessing the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of the study drug.